Somatic alterations as the basis for resistance to targeted therapies (Q38151570)

29 August 2017

Somatic alterations as the basis for resistance to targeted therapies (English)

1 reference

29 August 2017

Alberto Bardelli

2

0 references

author name string

Brian G Blair

series ordinal

1

1 reference

PubMed ID

24114654

29 August 2017

Ben Ho Park

series ordinal

3

1 reference

29 August 2017

1 January 2014

1 reference

29 August 2017

1 reference

29 August 2017

232

1 reference

29 August 2017

2

1 reference

29 August 2017

244-254

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

29 August 2017

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

Imatinib treatment for gastrointestinal stromal tumour (GIST).

21 January 2018

1 reference

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction

21 January 2018

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

21 January 2018

1 reference

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors

21 January 2018

1 reference

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

21 January 2018

1 reference

Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma

21 January 2018

1 reference

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

21 January 2018

1 reference

TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.

21 January 2018

1 reference

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

21 January 2018

1 reference

Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor

21 January 2018

1 reference

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

Rituximab: mechanism of action

21 January 2018

1 reference

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

21 January 2018

1 reference

Genetic predisposition syndromes and their management

21 January 2018

1 reference

Involvement of Brca2 in DNA repair

21 January 2018

1 reference

BRCA2 is required for homology-directed repair of chromosomal breaks

21 January 2018

1 reference

Brca1 controls homology-directed DNA repair

21 January 2018

1 reference

Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein

21 January 2018

1 reference

The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA.

21 January 2018

1 reference

Recombinational repair and restart of damaged replication forks.

21 January 2018

1 reference

PARP inhibition: PARP1 and beyond

21 January 2018

1 reference

Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks

21 January 2018

1 reference

Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography

21 January 2018

1 reference

DNA repair pathways as targets for cancer therapy

21 January 2018

1 reference

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

Drug resistance caused by reversion mutation

21 January 2018

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

21 January 2018

1 reference

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

21 January 2018

1 reference

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

21 January 2018

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

Molecular targets for breast cancer therapy and prevention

21 January 2018

1 reference

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

Update on clinical trials: genetic targets in breast cancer

21 January 2018

1 reference

The role of targeted therapy and biomarkers in breast cancer treatment

21 January 2018

1 reference

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?

21 January 2018

1 reference

The PIK3CA gene as a mutated target for cancer therapy

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

21 January 2018

1 reference

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

21 January 2018

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines

21 January 2018

1 reference

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models

21 January 2018

1 reference

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

Current approaches and future directions in the treatment of HER2-positive breast cancer

21 January 2018

1 reference

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib

21 January 2018

1 reference

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

21 January 2018

1 reference

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

21 January 2018

1 reference

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

Treatment and detection of ALK-rearranged NSCLC.

21 January 2018

1 reference

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

21 January 2018

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

21 January 2018

1 reference

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations

21 January 2018

1 reference

Targeting phosphoinositide 3-kinase: moving towards therapy

21 January 2018

1 reference

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11156

Identifiers

DOI

10.1002/PATH.4278

1 reference

29 August 2017

1 reference

PubMed ID

24114654